Apogee is seeking to reshape the current standard of care for inflammatory and immune diseases because we believe people living with these diseases deserve the best possible treatment.
Our pipeline of novel antibody therapeutics targets well-established biological drivers and development pathways and has the potential to treat numerous dermatological, respiratory, and gastroenterological conditions.
People first, always